The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.95
Bid: 1.90
Ask: 2.00
Change: 0.05 (2.63%)
Spread: 0.10 (5.263%)
Open: 1.90
High: 2.00
Low: 1.95
Prev. Close: 1.90
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 11:00

RNS Number : 3512B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nutrition-Wellness Venture SA

City and country of registered office (if applicable)

Vevey, Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

16 March 2023 and 9 May 2023 (post AOP conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

7.85%

0%

7.85%

56,008,541

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

7.85%

0%

SUBTOTAL 8. A

56,008,541

7.85%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Nestle S.A.

7.85%

7.85%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMPJ
Date   Source Headline
3rd May 20185:26 pmRNSHolding(s) in Company
2nd May 201811:00 amRNSPrice Monitoring Extension
11th Apr 20187:00 amRNSPreliminary Results for the Year Ended 31 Dec 17
6th Apr 20187:00 amRNSAppointment of Non-Executive Director
6th Apr 20187:00 amRNSResults of Pre-Submission Meeting with FDA
27th Mar 20187:00 amRNSBroadening of Feraccru indication
16th Mar 20187:00 amRNSUpdate on the AEGIS-CKD study
23rd Feb 20181:56 pmRNSReceives CHMP positive opinion on Feraccru®
22nd Feb 20187:00 amRNSBusiness and Trading Update
5th Feb 20187:00 amRNSTop-line results from Feraccru Phase III study
29th Jan 20187:00 amRNSNotice of Results
25th Jan 20187:00 amRNSGrant of share options
10th Oct 20177:00 amRNSCompletion of patient enrolment in Phase 3 study
5th Oct 20177:00 amRNSPDMR Acquisition of Shares
20th Sep 20177:00 amRNSInterim Report
14th Sep 20177:00 amRNSBoard Change
6th Sep 20177:00 amRNSUS Composition of Matter Patent Allowed
31st Aug 20177:00 amRNSShield to Present at Baird Healthcare Conference
15th Aug 20177:00 amRNSNotice of Results
11th Jul 20172:59 pmRNSGrant of Share Options
10th Jul 20174:16 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSFeraccru licence agreement for Switzerland
5th Jul 201712:38 pmRNSHolding(s) in Company
3rd Jul 201712:34 pmRNSWarrant Exercise and Expiry
28th Jun 201710:37 amRNSHolding(s) in Company
28th Jun 20178:00 amRNSAdmission of New Ordinary Shares
22nd Jun 20177:00 amRNSBiomarker data on ferric maltol in patients
15th Jun 20171:59 pmRNSResults of Fundraise
15th Jun 20177:00 amRNSProposed Fundraise
13th Jun 20172:40 pmRNSResult of AGM
26th May 20177:00 amRNSAppointment of Joint Broker
28th Apr 20177:00 amRNSAnnual Report, Accounts and AGM Notification
4th Apr 20177:00 amRNSAppointment of Chief Financial Officer
4th Apr 20177:00 amRNSPreliminary Results for the Year Ended 31 Dec 2016
13th Mar 20177:00 amRNSNotice of Results
13th Mar 20177:00 amRNSIP Portfolio Update
30th Jan 201710:50 amRNSDirectorate and Secretarial Update
6th Jan 20177:00 amRNSBusiness Update
7th Nov 20167:00 amRNSBoard Change
20th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
13th Sep 20169:25 amRNSGrant of Share Awards
7th Sep 20167:37 amRNSComposition of Matter Patent Granted on Feraccru®
7th Sep 20167:00 amRNSComposition of Matter Patent Granted on Feraccru®
15th Aug 201612:22 pmRNSNotice of Results
4th Aug 201611:05 amRNSResult of AGM
1st Aug 201612:00 pmRNSPresenting at Canaccord Genuity Conference, Boston
30th Jun 20165:06 pmRNS2015 Annual Report and Accounts and Notice of AGM
14th Jun 20167:00 amRNSMaiden Preliminary Results for FY15
23rd Mar 20167:00 amRNSNotice of results and change of accounting date
11th Mar 20167:00 amRNSGrant of Share Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.